SIMVASTATIN as a potential protective strategy against doxorubicin-induced cardiotoxicity - Takeaways - MDSpire

SIMVASTATIN as a potential protective strategy against doxorubicin-induced cardiotoxicity

  • By

  • Barbara Pala

  • Mariagrazia Piscione

  • Maria Carmela Di Marcantonio

  • Francesco Cribari

  • Roberta Vitale

  • Thomas Baldi

  • Ada Popolo

  • Gabriella Mincione

  • June 9, 2026

  • 0 min

Share

  • 1

    Doxorubicin-induced cardiotoxicity (DIC) can lead to significant cardiac complications, limiting its use in cancer treatment.

  • 2

    Simvastatin, a lipophilic statin, may provide cardioprotection through antioxidant and anti-inflammatory effects beyond cholesterol lowering.

  • 3

    In a study of 80 oncology patients, simvastatin use was associated with fewer electrocardiographic abnormalities during anthracycline therapy.

  • 4

    Statin-treated patients experienced smaller declines in left ventricular ejection fraction and reduced QT/QTc prolongation compared to non-users.

  • 5

    The findings suggest that simvastatin may mitigate early cardiac dysfunction and preserve ventricular function in patients receiving doxorubicin.

Original Source(s)

SIMVASTATIN as a potential protective strategy against doxorubicin-induced cardiotoxicity

  • by Barbara Pala, Mariagrazia Piscione, Maria Carmela Di Marcantonio, Francesco Cribari, Roberta Vitale, Thomas Baldi, Ada Popolo, Gabriella Mincione

  • June 9, 2026

Related Content

Cardiac Risk Associated with Radiotherapy for Left-Sided Breast Cancer

Shared genetic associations and aetiology between obstructive sleep apnoea and cardiovascular diseases: a genome-wide cross-trait analysis and bidirectional Mendelian randomization analysis

Early detection value of miR-29a in patients with acute myocardial infarction